Press Release: 3/21/2025

Brown Rudnick Advises on IP for Latigo’s $150M Series B Financing

 

PUBLISHED ON: 03/20/2025

Brown Rudnick advised Latigo Biotherapeutics on IP matters related to its $150 million Series B financing to develop nonopioid pain medication.

The financing, announced on March 17, 2025, was led by Blue Owl Capital and included Deep Track Capital, Access Biotechnology, Qatar Investment Authority and Sanofi Ventures.

Latigo will use the proceeds to support the advancement of its highly selective Nav1.8 inhibitors currently in clinical development for the non-opioid treatment of pain, as well as the development of Latigo’s broader pipeline.

“The need for non-opioid pain treatments has never been more urgent, and this financing allows us to accelerate the development of our robust portfolio of pain medicines that have the potential to transform the treatment landscape,” said Nima Farzan, chief executive officer of Latigo Biotherapeutics. “We appreciate the support of our new and existing investors as we work to bring best-in-class, non-addictive pain treatments to patients.”

Latigo, based in Thousand Oaks, Calif., was founded by Westlake in 2020. The company’s proprietary, in-house technology generates novel drugs against targets validated by human genetics using the most advanced artificial intelligence, machine learning, structure-based, and knowledge-based design techniques to optimize potency and selectivity.

Brown Rudnick also provided IP counsel to Latigo on its $135 million Series A financing in 2024.

The Brown Rudnick team was led by partner Adam Schoen and included associate Amit Singhai and senior patent agent Hugo Garrido.